We are live on ! Find out more
Swiss National Bank

Swiss National Bank Portfolio holdings

AUM $191B
1-Year Est. Return 45.21%
 

The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.

This Fund
S&P 500
This Quarter Est. Return
-3.16%
1 Year Est. Return
+45.21%
3 Year Est. Return
+136.44%
5 Year Est. Return
+183.49%
10 Year Est. Return
+678.03%
AUM
$177B
AUM Growth
+$11.2B
Cap. Flow
+$20.2B
Cap. Flow %
11.39%
Top 10 Hldgs %
27.51%
Holding
2,722
New
3
Increased
2,642
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$1.38B
2
MSFT icon
Microsoft
MSFT
+$1.13B
3
AMZN icon
Amazon
AMZN
+$756M
4
TSLA icon
Tesla
TSLA
+$466M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$431M

Sector Composition

Rank Sector Weight
1 Technology 28.22%
2 Healthcare 14.23%
3 Consumer Discretionary 13.07%
4 Communication Services 9.53%
5 Industrials 8.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCRT icon
2651
Alaunos Therapeutics
TCRT
$4.88M
$333K ﹤0.01%
3,407
+258
+8% +$33.1K
TRHC
2652
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$333K ﹤0.01%
57,800
+5,700
+11% +$51.2K
RMO
2653
DELISTED
Romeo Power, Inc.
RMO
$331K ﹤0.01%
222,100
+19,100
+9% +$40.2K
CUE icon
2654
Cue Biopharma
CUE
$128M
$330K ﹤0.01%
2,253
+170
+8% +$36K
ALXO icon
2655
ALX Oncology
ALXO
$278M
$324K ﹤0.01%
19,200
+1,500
+8% +$25.6K
ORIC icon
2656
Oric Pharmaceuticals
ORIC
$1.43B
$324K ﹤0.01%
60,600
+4,300
+8% +$38.7K
SGHT icon
2657
Sight Sciences
SGHT
$456M
$324K ﹤0.01%
28,000
+1,900
+7% +$29.2K
RSKD icon
2658
Riskified
RSKD
$846M
$320K ﹤0.01%
53,000
+10,300
+24% +$68.8K
BGRY
2659
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
$305K ﹤0.01%
105,900
+7,900
+8% +$28.1K
LXRX icon
2660
Lexicon Pharmaceuticals
LXRX
$1.05B
$294K ﹤0.01%
140,800
+13,500
+11% +$37.4K
KRON
2661
DELISTED
Kronos Bio
KRON
$289K ﹤0.01%
40,000
+2,900
+8% +$24.7K
NKTX icon
2662
Nkarta
NKTX
$171M
$289K ﹤0.01%
25,400
AKBA icon
2663
Akebia Therapeutics
AKBA
$248M
$282K ﹤0.01%
393,085
+28,300
+8% +$60.5K
KNTE
2664
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$270K ﹤0.01%
24,000
TSHA icon
2665
Taysha Gene Therapies
TSHA
$2.05B
$267K ﹤0.01%
41,000
+3,500
+9% +$26.2K
AVIR icon
2666
Atea Pharmaceuticals
AVIR
$405M
$264K ﹤0.01%
36,500
QTTB icon
2667
Q32 Bio
QTTB
$458M
$256K ﹤0.01%
4,672
BCAB icon
2668
BioAtla
BCAB
$5.61M
$251K ﹤0.01%
1,004
+152
+18% +$63.6K
VIEW
2669
DELISTED
View, Inc. Class A Common Stock
VIEW
$236K ﹤0.01%
2,138
+146
+7% +$22.1K
SKYT
2670
DELISTED
SkyWater Technology
SKYT
$233K ﹤0.01%
21,500
QNCX icon
2671
Quince Therapeutics
QNCX
$31.8M
$222K ﹤0.01%
179
LOTZ
2672
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
$222K ﹤0.01%
161,700
+11,400
+8% +$21.5K
MILE
2673
DELISTED
Metromile, Inc. Common Stock
MILE
$220K ﹤0.01%
166,700
SPIR icon
2674
Spire Global
SPIR
$571M
$216K ﹤0.01%
12,875
PLRX icon
2675
Pliant Therapeutics
PLRX
$66.3M
$209K ﹤0.01%
29,800
+2,400
+9% +$24.5K

Similar funds

Swiss National Bank's Q1 2022 Portfolio in Review

As of Q1 2022, Swiss National Bank held 2,722 positions worth $177B, up 6.8% from $166B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Swiss National Bank deployed $20.2B of net new capital in Q1 2022, opening 3 new positions and adding to 2,642 existing holdings. Its largest new stake was Constellation Energy: 1,411,783 shares worth $79.4M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Exelon, an estimated $41.2M trimmed.

  • Swiss National Bank's largest Q1 2022 buy was Constellation Energy: 1,411,783 shares worth $79.4M.
  • Swiss National Bank added most to Apple in Q1 2022, an estimated $1.38B increase.
  • Swiss National Bank's biggest Q1 2022 reduction was Exelon, cutting an estimated $41.2M.
  • Swiss National Bank fully exited Xilinx Inc in Q1 2022, selling an estimated $199M.
  • Swiss National Bank's ten largest holdings make up 28% of its $177B portfolio in Q1 2022.
  • Swiss National Bank opened 3 new positions and closed 31 in Q1 2022.
  • Swiss National Bank's portfolio value rose 6.8% quarter-over-quarter to $177B.

Based on Swiss National Bank's 13F filing for Q1 2022, filed 9 May 2022.